Edwards Lifesciences (EW) Could Be 21% Undervalued After Earnings Guidance And Trial Data

Edwards Lifesciences (EW) is back in focus after a busy early November, with third quarter results, higher full year sales guidance and fresh clinical trial data all feeding directly into the stock move.

The recent flurry of earnings, guidance and clinical updates has coincided with a sharp turn in sentiment toward Edwards Lifesciences, with a 16.6% 1 month share price return and 18.2% year to date share price return contributing to a 22.3% 1 year total shareholder return. This suggests that momentum has picked up after a tougher longer term stretch that still leaves the 5 year total shareholder return down 11.8%.

Scan how Edwards Lifesciences fits alongside other procedure-driven healthcare stocks by comparing it with a curated 34 healthcare AI stocks list that is already in motion.

After a 1 month surge and a tight 2% gap to the average analyst target, Edwards Lifesciences now trades well above one fair value estimate that implies a discount of about 21%. Which anchor matters more for you?

Most Popular Narrative: 10% Undervalued

On the most followed view, Edwards Lifesciences carries a fair value of about $101 compared with a last close of $100.82. The story really comes down to whether the underlying growth and margin plan holds together under a 7.5% discount rate.

The main factor that has to go right is successful execution on the multi-platform structural heart strategy. This includes TMTT growth toward the stated 2030 revenue goal and continued translation of long-term clinical data into physician preference.

See why 29 investors see Edwards Lifesciences as 0% undervalued.

Result: Fair Value of $100.96 (UNDERVALUED)

Still, the thesis around Edwards Lifesciences can wobble if tariff pressures squeeze margins further or if legal and governance issues erode investor confidence.

Find out about the key risks to this Edwards Lifesciences narrative.

Another View: Edwards Lifesciences Through The P/E Lens

There is a very different picture when Edwards Lifesciences is viewed through simple earnings multiples. The stock trades on a P/E of 58.3x, while the fair ratio is 34.8x and the US Medical Equipment group sits at 26.5x with peers at 29.9x. That sort of gap lifts valuation risk for anyone buying purely off the latest momentum. Which signal do you weigh more: the narrative fair value near $101, or a multiple profile that looks stretched on almost every comparison?

To see how those earnings ratios stack up in more detail, including what the fair ratio might move toward if sentiment cools, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed signals on Edwards Lifesciences so far. If you want to move fast and build your own stance off the underlying data, weigh up the 1 key reward and 2 important warning signs.

Looking for more investment ideas beyond Edwards Lifesciences?

If you stop with Edwards Lifesciences, you only see one angle. Broaden your watchlist and you give yourself more ways for the numbers to work in your favor.

• Target stronger upside potential by scanning a focused pool of quality companies that currently look mispriced using the 42 high quality undervalued stocks.
• Protect your downside by assessing a 32 resilient stocks with low risk scores that highlights businesses with sturdier financial profiles and fewer red flags.
• Get ahead of the crowd by reviewing a 21 high quality undiscovered gems that surfaces lesser-known stocks with solid fundamentals before attention catches up.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com